SCHEMBL20067555

SCHEMBL20067555

CN(CCNCCO)C(=O)OC(C)(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 2/20 0.41
FPR3 P25089 1/20 0.38
FPR2 P25090 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
AAK1 Q2M2I8 1/20 0.35
HDAC6 Q9UBN7 2/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
CTSK P43235 3/20 0.34
GPR88 Q9GZN0 1/20 0.33
METAP2 P50579 1/20 0.33
PDK2 Q15119 1/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA7 P43166 1/20 0.32
CHRNB2 P17787 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
CHRNA4 P43681 1/20 0.32
GBA1 P04062 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26900686 0.93 CA14 (0.41) CA14FPR3FPR2TDP1AAK1
SCHEMBL30999444 0.90 TDP1 (0.42) CA14FPR3FPR2TDP1AAK1
SCHEMBL30511022 0.88 CYP2C9 (0.39) CA14FPR3FPR2TDP1AAK1
SCHEMBL15223854 0.87 PAOX (0.46) CA14FPR3FPR2TDP1AAK1
SCHEMBL13355834 0.86 FPR3 (0.38) CA14FPR3FPR2TDP1AAK1
SCHEMBL19885951 0.86 CA14 (0.37) CA14FPR3FPR2TDP1AAK1
SCHEMBL23607647 0.85 CYP2C9 (0.46) CA14FPR3FPR2TDP1AAK1
SCHEMBL28997883 0.85 TDP1 (0.44) CA14FPR3FPR2TDP1AAK1
SCHEMBL12287335 0.85 FPR3 (0.37) CA14FPR3FPR2TDP1AAK1
SCHEMBL9269202 0.84 FPR3 (0.39) CA14FPR3FPR2TDP1AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383915-A1 OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER GENENTECH, INC. (US) 2024-11-21 US disclosed
EP-4320132-A1 OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER Genentech, Inc. (US) 2024-02-14 EP disclosed
US-20230069963-A1 PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND TAISHO PHARMACEUTICAL CO., LTD. (JP) 2023-03-09 US disclosed
WO-2022216762-A1 OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER GENENTECH, INC. (US) 2022-10-13 WO disclosed
EP-3903788-A1 PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND Taisho Pharmaceutical Co., Ltd. (JP) 2021-11-03 EP disclosed
US-10815194-B2 Process for the preparation of mono-protected α,ω-diamino alkanes BYONDIS B.V. (NL) 2020-10-27 US disclosed
EP-3525826-B1 NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF BYONDIS BV (NL) 2020-07-22 EP disclosed
WO-2020138015-A1 PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND 大正製薬株式会社 2020-07-02 WO disclosed
WO-2018069375-A1 NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF SYNTHON BIOPHARMACEUTICALS B.V. (NL) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815194-B2 Process for the preparation of mono-protected α,ω-diamino alkanes FCGRT, CD22, DEGS1 CA14 1091/4885FPR3 1506/4885FPR2 984/4885
US-20230069963-A1 PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND ZC3HAV1, ZC3HAV1L, IL5 CA14 3049/4885FPR3 504/4885FPR2 757/4885
US-20240383915-A1 OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER OXA1L, GRIK4, GRIK5 CA14 298/4885FPR3 1195/4885FPR2 1430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.